BRCA2 and neoplasm: This revealed a somatic BRCA2 mutation (c.5446_5449delCTAG, p.Ser1816Leu fs*23) with a high tumour variant allele frequency (VAF, 73%) indicating likely loss‐of‐heterozygosity of BRCA2. In September 2016, she began maintenance olaparib treatment (Table 2, treatment 4).